AB0434 The Role of IGG Anti [beta]2-GPI in The Clinical Manifestations of Systemic Lupus Erythematosus

Background Beta 2 GPI is an important antigenic target for antiphospholipid antibodies. The role of IgG antibodies to β2 glycoprotein I [Anti-β2-GPI] has been well defined in antiphospholipid antibody syndrome but its role in the clinical manifestions of SLE remains elusive. Objectives To investigat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75, p.1055
Hauptverfasser: Mahendran, B, Sankalingam, R, Mohanasundaram, K, Sankaran, S, Mani, M, Chilukuri, B
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1055
container_title Annals of the rheumatic diseases
container_volume 75
creator Mahendran, B
Sankalingam, R
Mohanasundaram, K
Sankaran, S
Mani, M
Chilukuri, B
description Background Beta 2 GPI is an important antigenic target for antiphospholipid antibodies. The role of IgG antibodies to β2 glycoprotein I [Anti-β2-GPI] has been well defined in antiphospholipid antibody syndrome but its role in the clinical manifestions of SLE remains elusive. Objectives To investigate the role of Anti-β2-GPI in the clinical manifestations of SLE Methods IgG Anti-β2-GPI was measured in 184 patients with SLE (93% women, mean age 28 years). IgG Anti-β2-GPI (>18 GPL units) was found in 19 patients (10.3%). Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Results Of the patients with SLE who demonstrated IgG Anti-β2-GPI, 31% had at least one thrombotic event (OR 4.2, p=0.01), 26% had pulmonary hypertension (OR 3.2, p=0.02) and 26% had recurrent abortions (OR 4.1, p=0.02). IgG Anti-β2-GPI was protective against lupus nephritis (OR 0.31, p=0.02). No other manifestations were significantly higher in patients with IgG Anti-β2-GPI positivity Clinical Manifestation Anti-β (2)-GPI --- Positive Negative --- Recurrent abortions Present 5 13 OR 4.1 p=0.02 Absent 14 152 Thrombotic events Present 6 16 OR 4.2 p=0.01 Absent 13 149 Pulmonary hypertension Present 5 15 OR 3.2 p=0.02 Absent 14 150 Lupus nephritis Present 6 98 OR 0.31 p=0.02 Absent 13 67 Conclusions In SLE, IgG Anti-β2-GPI is associated with thrombotic events and pulmonary hypertension, but may have a protective effect against lupus nephritis. Large scale studies are required to confirm these findings. References Vikerfors A, Johansson AB, Gustafsson JT, Jönsen A, Leonard D, Zickert A et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford). 2013 Mar;52(3):501-9. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B et al. Obstetric and vascular APS: same autoantibodies but different diseases? Lupus. 2012 Jun;21(7):708-10. Matsuura E, Shen L, Matsunami Y, Quan N, Makarova M, Geske FJ et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus. 2010 Apr;19(4):379-84. Disclosure of Interest None declared
doi_str_mv 10.1136/annrheumdis-2016-eular.2603
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1901813944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322510085</sourcerecordid><originalsourceid>FETCH-proquest_journals_19018139443</originalsourceid><addsrcrecordid>eNqNjN1KAzEUhIMouP68w4Fep55sQty9rKWuBQXR3omUWLNsSjapOclF395VfACvhpn5ZhibCZwLIfWNCSENtoyfjniNQnNbvEnzWqM8YZVQuplijaesQkTJVatvz9kF0X6y2IimYv3iDpVUsBksvERvIfaw7jpYhOzg7cNm817z7nkNLvwyS--C2xkPTya43lI22cVAP7PXI2U7uh08lkMhWKVjHuxocqRCV-ysN57s9Z9estn9arN84IcUv8p0s93HksJUbUWLohGyVUr-j_oGGkZQFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901813944</pqid></control><display><type>article</type><title>AB0434 The Role of IGG Anti [beta]2-GPI in The Clinical Manifestations of Systemic Lupus Erythematosus</title><source>BMJ Journals - NESLi2</source><creator>Mahendran, B ; Sankalingam, R ; Mohanasundaram, K ; Sankaran, S ; Mani, M ; Chilukuri, B</creator><creatorcontrib>Mahendran, B ; Sankalingam, R ; Mohanasundaram, K ; Sankaran, S ; Mani, M ; Chilukuri, B</creatorcontrib><description>Background Beta 2 GPI is an important antigenic target for antiphospholipid antibodies. The role of IgG antibodies to β2 glycoprotein I [Anti-β2-GPI] has been well defined in antiphospholipid antibody syndrome but its role in the clinical manifestions of SLE remains elusive. Objectives To investigate the role of Anti-β2-GPI in the clinical manifestations of SLE Methods IgG Anti-β2-GPI was measured in 184 patients with SLE (93% women, mean age 28 years). IgG Anti-β2-GPI (&gt;18 GPL units) was found in 19 patients (10.3%). Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Results Of the patients with SLE who demonstrated IgG Anti-β2-GPI, 31% had at least one thrombotic event (OR 4.2, p=0.01), 26% had pulmonary hypertension (OR 3.2, p=0.02) and 26% had recurrent abortions (OR 4.1, p=0.02). IgG Anti-β2-GPI was protective against lupus nephritis (OR 0.31, p=0.02). No other manifestations were significantly higher in patients with IgG Anti-β2-GPI positivity Clinical Manifestation Anti-β (2)-GPI --- Positive Negative --- Recurrent abortions Present 5 13 OR 4.1 p=0.02 Absent 14 152 Thrombotic events Present 6 16 OR 4.2 p=0.01 Absent 13 149 Pulmonary hypertension Present 5 15 OR 3.2 p=0.02 Absent 14 150 Lupus nephritis Present 6 98 OR 0.31 p=0.02 Absent 13 67 Conclusions In SLE, IgG Anti-β2-GPI is associated with thrombotic events and pulmonary hypertension, but may have a protective effect against lupus nephritis. Large scale studies are required to confirm these findings. References Vikerfors A, Johansson AB, Gustafsson JT, Jönsen A, Leonard D, Zickert A et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford). 2013 Mar;52(3):501-9. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B et al. Obstetric and vascular APS: same autoantibodies but different diseases? Lupus. 2012 Jun;21(7):708-10. Matsuura E, Shen L, Matsunami Y, Quan N, Makarova M, Geske FJ et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus. 2010 Apr;19(4):379-84. Disclosure of Interest None declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.2603</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75, p.1055</ispartof><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Mahendran, B</creatorcontrib><creatorcontrib>Sankalingam, R</creatorcontrib><creatorcontrib>Mohanasundaram, K</creatorcontrib><creatorcontrib>Sankaran, S</creatorcontrib><creatorcontrib>Mani, M</creatorcontrib><creatorcontrib>Chilukuri, B</creatorcontrib><title>AB0434 The Role of IGG Anti [beta]2-GPI in The Clinical Manifestations of Systemic Lupus Erythematosus</title><title>Annals of the rheumatic diseases</title><description>Background Beta 2 GPI is an important antigenic target for antiphospholipid antibodies. The role of IgG antibodies to β2 glycoprotein I [Anti-β2-GPI] has been well defined in antiphospholipid antibody syndrome but its role in the clinical manifestions of SLE remains elusive. Objectives To investigate the role of Anti-β2-GPI in the clinical manifestations of SLE Methods IgG Anti-β2-GPI was measured in 184 patients with SLE (93% women, mean age 28 years). IgG Anti-β2-GPI (&gt;18 GPL units) was found in 19 patients (10.3%). Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Results Of the patients with SLE who demonstrated IgG Anti-β2-GPI, 31% had at least one thrombotic event (OR 4.2, p=0.01), 26% had pulmonary hypertension (OR 3.2, p=0.02) and 26% had recurrent abortions (OR 4.1, p=0.02). IgG Anti-β2-GPI was protective against lupus nephritis (OR 0.31, p=0.02). No other manifestations were significantly higher in patients with IgG Anti-β2-GPI positivity Clinical Manifestation Anti-β (2)-GPI --- Positive Negative --- Recurrent abortions Present 5 13 OR 4.1 p=0.02 Absent 14 152 Thrombotic events Present 6 16 OR 4.2 p=0.01 Absent 13 149 Pulmonary hypertension Present 5 15 OR 3.2 p=0.02 Absent 14 150 Lupus nephritis Present 6 98 OR 0.31 p=0.02 Absent 13 67 Conclusions In SLE, IgG Anti-β2-GPI is associated with thrombotic events and pulmonary hypertension, but may have a protective effect against lupus nephritis. Large scale studies are required to confirm these findings. References Vikerfors A, Johansson AB, Gustafsson JT, Jönsen A, Leonard D, Zickert A et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford). 2013 Mar;52(3):501-9. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B et al. Obstetric and vascular APS: same autoantibodies but different diseases? Lupus. 2012 Jun;21(7):708-10. Matsuura E, Shen L, Matsunami Y, Quan N, Makarova M, Geske FJ et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus. 2010 Apr;19(4):379-84. Disclosure of Interest None declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNjN1KAzEUhIMouP68w4Fep55sQty9rKWuBQXR3omUWLNsSjapOclF395VfACvhpn5ZhibCZwLIfWNCSENtoyfjniNQnNbvEnzWqM8YZVQuplijaesQkTJVatvz9kF0X6y2IimYv3iDpVUsBksvERvIfaw7jpYhOzg7cNm817z7nkNLvwyS--C2xkPTya43lI22cVAP7PXI2U7uh08lkMhWKVjHuxocqRCV-ysN57s9Z9estn9arN84IcUv8p0s93HksJUbUWLohGyVUr-j_oGGkZQFw</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Mahendran, B</creator><creator>Sankalingam, R</creator><creator>Mohanasundaram, K</creator><creator>Sankaran, S</creator><creator>Mani, M</creator><creator>Chilukuri, B</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20160601</creationdate><title>AB0434 The Role of IGG Anti [beta]2-GPI in The Clinical Manifestations of Systemic Lupus Erythematosus</title><author>Mahendran, B ; Sankalingam, R ; Mohanasundaram, K ; Sankaran, S ; Mani, M ; Chilukuri, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19018139443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahendran, B</creatorcontrib><creatorcontrib>Sankalingam, R</creatorcontrib><creatorcontrib>Mohanasundaram, K</creatorcontrib><creatorcontrib>Sankaran, S</creatorcontrib><creatorcontrib>Mani, M</creatorcontrib><creatorcontrib>Chilukuri, B</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahendran, B</au><au>Sankalingam, R</au><au>Mohanasundaram, K</au><au>Sankaran, S</au><au>Mani, M</au><au>Chilukuri, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0434 The Role of IGG Anti [beta]2-GPI in The Clinical Manifestations of Systemic Lupus Erythematosus</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06-01</date><risdate>2016</risdate><volume>75</volume><spage>1055</spage><pages>1055-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Beta 2 GPI is an important antigenic target for antiphospholipid antibodies. The role of IgG antibodies to β2 glycoprotein I [Anti-β2-GPI] has been well defined in antiphospholipid antibody syndrome but its role in the clinical manifestions of SLE remains elusive. Objectives To investigate the role of Anti-β2-GPI in the clinical manifestations of SLE Methods IgG Anti-β2-GPI was measured in 184 patients with SLE (93% women, mean age 28 years). IgG Anti-β2-GPI (&gt;18 GPL units) was found in 19 patients (10.3%). Associations were determined with clinical manifestations of SLE and with components of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index Results Of the patients with SLE who demonstrated IgG Anti-β2-GPI, 31% had at least one thrombotic event (OR 4.2, p=0.01), 26% had pulmonary hypertension (OR 3.2, p=0.02) and 26% had recurrent abortions (OR 4.1, p=0.02). IgG Anti-β2-GPI was protective against lupus nephritis (OR 0.31, p=0.02). No other manifestations were significantly higher in patients with IgG Anti-β2-GPI positivity Clinical Manifestation Anti-β (2)-GPI --- Positive Negative --- Recurrent abortions Present 5 13 OR 4.1 p=0.02 Absent 14 152 Thrombotic events Present 6 16 OR 4.2 p=0.01 Absent 13 149 Pulmonary hypertension Present 5 15 OR 3.2 p=0.02 Absent 14 150 Lupus nephritis Present 6 98 OR 0.31 p=0.02 Absent 13 67 Conclusions In SLE, IgG Anti-β2-GPI is associated with thrombotic events and pulmonary hypertension, but may have a protective effect against lupus nephritis. Large scale studies are required to confirm these findings. References Vikerfors A, Johansson AB, Gustafsson JT, Jönsen A, Leonard D, Zickert A et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford). 2013 Mar;52(3):501-9. Meroni PL, Raschi E, Grossi C, Pregnolato F, Trespidi L, Acaia B et al. Obstetric and vascular APS: same autoantibodies but different diseases? Lupus. 2012 Jun;21(7):708-10. Matsuura E, Shen L, Matsunami Y, Quan N, Makarova M, Geske FJ et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus. 2010 Apr;19(4):379-84. Disclosure of Interest None declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2016-eular.2603</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75, p.1055
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901813944
source BMJ Journals - NESLi2
title AB0434 The Role of IGG Anti [beta]2-GPI in The Clinical Manifestations of Systemic Lupus Erythematosus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T03%3A24%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0434%20The%20Role%20of%20IGG%20Anti%20%5Bbeta%5D2-GPI%20in%20The%20Clinical%20Manifestations%20of%20Systemic%20Lupus%20Erythematosus&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Mahendran,%20B&rft.date=2016-06-01&rft.volume=75&rft.spage=1055&rft.pages=1055-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.2603&rft_dat=%3Cproquest%3E4322510085%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901813944&rft_id=info:pmid/&rfr_iscdi=true